Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

Tissue expansion, originally developed for super-resolution imaging, has become a foundation for expansion omics (ExO), a ...

In this retrospective cohort analysis of dually eligible beneficiaries, at-risk Medicare Advantage (MA) was associated with higher quality and avoidable health care utilization compared with both ...

Some patients with primary open-angle glaucoma may develop a myopic shift after 1 month of omidenepag isopropyl treatment.